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ABSTRACT
We evaluated the diagnostic delay (time from first symptoms to diagnosis) in
100 pediatric patients with Crohn disease (CD) and 75 patients with
ulcerative colitis (UC). Median (interquartile range) diagnostic delay in
patients with CD was 4 (2–8) (range 0–82) months compared with 2 (1–7)
(range 0–52) months in patients with UC (P¼ 0.003). The time interval
from first physician visit to inflammatory bowel disease diagnosis was
longer in patients with CD and UC when compared to the time interval
from symptom onset to first physician visit (CD: median 3 vs 1 months,
P< 0.001; UC: median 2 vs 0 months, P< 0.001). No specific risk factors
were identified for the length of diagnostic delay. Measures should be taken
to reduce diagnostic delay.
KeyWords: Crohn disease, diagnostic delay, pediatric inflammatory bowel
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(JPGN 2017;64: 245–247)
D iagnosing inflammatory bowel disease (IBD) can be chal-lenging, especially in patients with mild clinical activity
and/or an overlap of symptoms with functional diseases. Diagnostic
delay can represent an issue in patients with IBD from different
countries, considering the literature reporting on patients experien-
cing symptoms for many years before IBD diagnosis (1–5). Diag-
nostic delay describes the time interval from first IBD symptom
onset until IBD is diagnosed. Diagnostic delay can be separated into
a patient’s related period (from symptom onset to the first visit of a
physician) and a physician-related period (from first physician visit
until IBD diagnosis is established). Both patient’s related delay and
physician’s related delay should be evaluated to identify where
future improvements might be possible (on patients’ or on phys-
icians’ side or both). Diagnostic delay may not only decrease
quality of life of affected patients but has a major clinical effect
as several studies have meanwhile demonstrated that treatment
success is increased if therapies are initiated early after disease
onset (6,7). In contrast to adult patients there is a paucity of studies
having evaluated the length of diagnostic delay and associated risk
factors in pediatric patients with IBD (8,9). We aimed to answer the
following questions: first, how long is diagnostic delay in pediatric
Crohn disease (CD) and ulcerative colitis (UC) patients? Second,
which length of diagnostic delay is attributed to patient’s delay and
which length to physician’s delay? And third, what are risk factors
for long diagnostic delay in pediatric patients with CD and UC?
METHODS
Data from the nationwide Swiss Inflammatory Bowel Dis-
ease cohort study (SIBDCS) were analyzed. The SIBDCS has been
What Is Known
 Diagnostic delay in inflammatory bowel disease des-
cribes the time from symptom onset until diagnosis.
 Diagnostic delay can be divided into a patient-
dependent and a physician-dependent interval.
 Data on length of diagnostic delay and associated risk
factors are rare.
What Is New
 Median diagnostic delay in pediatric patients with
Crohn disease was 4 months compared to 2 months
in patients with ulcerative colitis.
 Physician-related delay was significantly longer than
patient-related delay.
 Measures should be undertaken to reduce diagnostic
delay.
Received March 9, 2016; accepted April 11, 2016.
From the Division of Gastroenterology and Hepatology, Centre
Hospitalier Universitaire Vaudois et Universite´ de Lausanne, Lausanne,
the yDivision of Gastroenterology and Hepatology, Triemlispital, the
zDivision of Gastroenterology and Hepatology, University Hospital
Zurich, Zurich, the §Institute of Social and Preventive Medicine, Uni-
versity of Bern, Bern, the jjInstitute of Social and Preventive Medicine,
Centre Hospitalier Universitaire Vaudois et Universite´ de Lausanne,
Lausanne, the Division of Gastroenterology and Hepatology, Univer-
sity Hospital Basel, Basel, the #Division of Pediatric Gastroenterology
and Nutrition, Centre Hospitalier Universitaire Vaudois et Universite´ de
Lausanne, Lausanne, the Division of Gastroenterology and Nutrition,
and the yyChildren’s Research Centre, University Children’s Hospital
Zurich, Zurich, Switzerland.
Address correspondence and reprint requests to Alain M. Schoepfer, MD,
PDþMER1, Division of Gastroenterology and Hepatology, Centre
Hospitalier Universitaire Vaudois/CHUV, Rue du Bugnon 46, 1011
Lausanne, Switzerland (e-mail: alain.schoepfer@chuv.ch).
Drs Schoepfer and Vavricka contributed equally to this article and share co-
first authorship.
This work was supported by research grants from the Swiss National Science
Foundation (33CS30_148422 to Swiss IBD Cohort Study group,
32003B_160115/1 to AMS, 310030–120312 to GR, 320000-114009/3,
and 32473B_135694/1 to SRV), and unrestricted research grants from
Otsuka Switzerland, Takeda Switzerland, and Tillotts Switzerland. This is
an investigator-initiated study; pharmaceutical companies played no role in
study design, acquisition, analysis, interpretation, or presentation of the data.
The authors report no conflicts of interest.
Copyright # 2016 by European Society for Pediatric Gastroenterology,
Hepatology, and Nutrition and North American Society for Pediatric
Gastroenterology, Hepatology, and Nutrition
DOI: 10.1097/MPG.0000000000001238
ORIGINAL ARTICLE: GASTROENTEROLOGY: INFLAMMATORY BOWEL DISEASE
JPGN  Volume 64, Number 2, February 2017 245
 Copyright © ESPGHAN and NASPGHAN. All rights reserved.
including pediatric and adult IBD from all over Switzerland starting
in 2006. The cohort study is supported by the Swiss National
Science Foundation and approved by the local ethical committees
(10). Data acquisition focuses on clinical, socioeconomic, and
psychosocial data. Written informed consent is mandatory for
inclusion into this cohort. Pediatric patients are included from 1
to 17 years of age. Detailed questionnaires focusing on physician-
reported outcomes are completed by the IBD physicians, whereas
parent-reported outcomes questionnaires are completed by parents
together with the affected child. The following analysis evaluates all
pediatric patients with CD and UC included into the SIBDCS from
October 2006 until July 2013. Patients included in the present study
were recruited in the following setting of care: 80% university
hospitals and 20% regional hospitals. All pediatric gastroenterol-
ogists in Switzerland work in a hospital setting, no one works in a
private practice.
The questionnaires recorded 3 distinct time intervals: first,
the time interval from first IBD symptoms to first consultation with
the physician (the length of this period is mainly dependent on the
patient and parents); second, the time interval from physician visit
to IBD diagnosis (the length of this period is mainly dependent on
the treating physicians); and third, the time from first IBD symp-
toms to IBD diagnosis (interval 1þ2).
Results of quantitative data are presented either as median
plus interquartile ranges (IQR; for non-Gaussian data) or
meanSD and range (for Gaussian data). The Kruskal-Wallis rank
test was used to analyze non-Gaussian quantitative data and to
evaluate whether there was a difference in diagnostic delay between
the distinct IBD groups (CD, UC). Time delays were then further
evaluated by pairwise comparisons using the Wilcoxon rank-sum
test with a Bonferroni adjustment. Differences in categorical distri-
bution between groups were evaluated using the Chi square test, or
the Fisher exact test in case of small sample size. A P< 0.05 was
considered statistically significant. A Cox proportional hazards
model was calculated to evaluate the length of diagnostic delay
with potentially associated factors.
RESULTS
A total of 175 pediatric patients with IBD were recruited,
whereof 100 patients (57.1%) had CD, and 75 (42.9%) had UC.
Median (IQR) age at enrolment was 14.1 (12.1–15.5) years in
patients with CD and 13.6 (11.6–15.3) years in patients with UC.
Median age at disease onset was 12 (10–14) years in patients with
CD and 11 (7–13) years in patients with UC. Disease location at
diagnosis in patients with CD was as follows: ileal, colonic,
ileocolonic, upper gastrointestinal tract in 8%, 10%, 47%, and
2% of patients, respectively (the remainder had combinations of
these disease locations). Patients with UC presented at diagnosis in
72% with pancolitis, 13.3% with left-sided colitis, and 6.7% with
proctitis (8% with unknown disease location).
The analysis of the different time intervals is presented by
means of comparative box plots in Figure 1 and by Table 1. Median
(IQR) time from first symptoms to IBD diagnosis was 4 (2–8)
months in CD compared to 2 (1–7) months in patients with UC.
Diagnostic delay in CD was significantly longer than that in UC
(P¼ 0.003). Time from first symptoms to physician visit (median,
IQR) was 1 month (0–3) in CD compared to 0 months in UC (0–3).
No difference between CD and UC was found for the time interval
from first symptoms to physician visit (P¼ 0.257). The time
interval from first physician visit to IBD diagnosis (median,
IQR, range) was 3 months (1–9) for patients with CD and 2 months
(1–4) for patients with UC. Again, no difference was found for this
time interval between patients with CD and UC (CD vs UC:
P¼ 0.111). Furthermore, time from physician visit to IBD diagnosis
was longer than the interval from symptom onset to physician visit
in patients with CD (median 3 vs 1 months, P< 0.001) and patients
with UC (median 2 vs 0 months, P< 0.001).
We further evaluated the effect of disease-associated factors
on diagnostic delay in children with IBD. In both CD and UC
patients the Cox proportional hazards model did not find any
significant association between the length of diagnostic delay
and the following factors: sex, age at IBD diagnosis, initial disease
location, positive family history of IBD (at least 1 first-degree
relative with IBD), provenience of parents (urban vs rural), nor
education level of the parents.
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FIGURE 1. Comparative box plots illustrating the different time
intervals of diagnostic delay (in months) according to diagnosis.
The box contains the 25th to the 75th percentile of the values, the
horizontal line in the box corresponds to the median. CD ¼ Crohn
disease; IBD ¼ inflammatory bowel disease; UC ¼ ulcerative colitis.
TABLE 1. Time delays (mo) in children with Crohn disease (n¼100)
and ulcerative colitis (n¼75), stratified according to overall diagno-
stic delay and time from first symptoms to physician visit and
from physician visit to establishment of inflammatory bowel disease
diagnosis
Time intervals, mo
Time from
first symp-
toms to IBD
diagnosis
Time from
first symp-
toms to phys-
ician visit
Time from
physician
visit to IBD
diagnosis
Disease percentile, % CD UC CD UC CD UC
1 0 0 0 0 0 0
5 1 0 0 0 0 0
10 1 1 0 0 0 0
25 2 1 0 0 1 1
50 4 2 1 0 3 2
75 8 7 3 3 9 4
90 19 12 6 6 19 10
95 24 22 11 12 27 15
99 82 52 24 36 82 20
Range 0–82 0–52 0–24 0–36 0–82 0–20
The listing of percentiles allows the readout of the percentage of patients
diagnosed at specific time intervals.
CD¼Crohn disease; IBD¼ inflammatory bowel disease; UC¼ ulcerative
colitis.
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DISCUSSION
Our study is the first one to systematically assess distinct
time intervals of diagnostic delay in pediatric patients with IBD and
has several clinically important messages. First, diagnostic delay is
longer in children with CD compared to children with UC. Second,
parents seem to address children quickly for workup of IBD-related
complaints, whereas the period from first physician visit to estab-
lishment of the IBD diagnosis may require some time. And third, no
specific risk factors could be identified for the length of diagnostic
delay in children with CD or UC.
In children with CD the median diagnostic delay from first
symptom onset to diagnosis was 4 months, which is significantly
longer than that in patients with UC (2 months). Our data are in
accordance with 3 studies that systematically evaluated the diag-
nostic delay in pediatric patients with IBD. Sawczenko and Sandhu
(9) evaluated diagnostic delay among 739 newly diagnosed
pediatric patients with IBD in Great Britain and Ireland. They
found a median diagnostic delay of 5 months. Diagnostic delay was
comparable when comparing CD patients with persons experien-
cing UC (median 0.5 vs 0.4 years). Similar to our data, they found
that one-fifth of the IBD population presented with a delay of more
than 1 year. Delays were most common in patients with CD and in
younger children. Of note, only 1 quarter of patients with CD
presented with the classical symptoms of diarrhea, weight loss, and
abdominal pain (9). Our Swiss data are in line with findings from
Heikenen and coworkers (8) who found an average diagnostic delay
of 7.1 months in patients with CD and 6.7 months in patients with
UC. Length of diagnostic delay in patients with CD depended on
disease location (10.5 months for small intestinal CD; 7.5 months
for ileocolonic CD; and 6.4 months for colonic CD). They found
that children experiencing growth failure presented with the longest
diagnostic delay. In contrast to the findings described by Sawc-
zenko, most patients with IBD presented with abdominal pain,
diarrhea, hematochezia, and weight loss. Timmer and coworkers
(11) evaluated the length of diagnostic delay in a German group of
2436 pediatric patients with IBD. They documented a median
diagnostic delay of 4 (IQR 2–8) months. Patients with CD experi-
encing ileal location were found to be associated with delayed
diagnosis. In line with data from Heikenen, the authors found that
growth failure was observed more frequently in patients with
delayed diagnosis. In contrast, the chances for early diagnosis
increased with increasing age (11).
How can we reduce the diagnostic delay in pediatric patients
with IBD? Our data reveal that pediatric patients with IBD are
referred relatively quickly to the physician. There may, however,
be a problem with a delay on physician’s side. We think that the use of
fecal biomarkers such as fecal calprotectin or lactoferrin has the
potential to reduce diagnostic delay in pediatric patients with IBD
(12,13). The high sensitivity of fecal calprotectin in detecting bowel
inflammation can help in the decision which patients are in need for
rapid endoscopic workup (12,13). The question may arise if it is at all
clinically relevant to keep the diagnostic delay as short as possible.
Increasing evidence indicates that this should indeed be a primary
goal given the increased therapy success in early disease (14–16).
In summary, we demonstrate in a large nationwide Swiss
cohort that the diagnostic delay in patients with CD is significantly
longer than that in patients with UC. Increased awareness among
members of general public and health practitioners is mandatory to
decrease the diagnostic delay in pediatric patients with IBD.
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